Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 16Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Colorectal Neoplasms 713Pancreatic Neoplasms 500Carcinoma, Hepatocellular 333Colonic Neoplasms 282Stomach Neoplasms 277Rectal Neoplasms 236Esophageal Neoplasms 198Neoplasms 194Liver Neoplasms 169Neoplasm Metastasis 164Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 111Cholangiocarcinoma 91Ovarian Neoplasms 87Lung Neoplasms 85Gastrointestinal Neoplasms 80Melanoma 76Gastrointestinal Stromal Tumors 68Adenocarcinoma Of Esophagus 64Adenocarcinoma 62Prostatic Neoplasms 59Biliary Tract Neoplasms 58Carcinoma, Renal Cell 56Sarcoma 54Head and Neck Neoplasms 54Urinary Bladder Neoplasms 51Gallbladder Neoplasms 49Barrett Esophagus 49Bile Duct Neoplasms 47Anus Neoplasms 47

Interventions

Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Venous Thromboembolism × Gastrointestinal × Clear all
NCT00966277 2016-12-12

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

M.D. Anderson Cancer Center

Phase 4 Completed
87 enrolled 9 charts
Classical hematologyGastrointestinal

Pancreatic Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡